Research Services

(CVD) Covance Augments Singapore Facility

Covance Inc. (CVD) recently announced that it had completed the expansion of its central laboratory facility in Singapore. Following the expansion of the laboratory by 50%, the company will be able to meet the demand for drug development...

27Apr2013 | | Comments Off on (CVD) Covance Augments Singapore Facility | Continued

(ABCO) The Advisory Board Company Value Alert

Texas ( Mar. 04, 2013) Wax Ink has issued a No Investment Interest rating for The Advisory Board Company (Nasdaq: | Comments Off on (ABCO) The Advisory Board Company Value Alert | Continued

(SNMX) Senomyx Leads ValuEngine.com Forecast Screen

Flavoring manufacturer Senomyx uses proprietary taste receptor technologies to discover and develop novel flavor ingredients in the savory, sweet, salt, bitter, and cooling areas. Senomyx has entered into flavoring manufacturer product discovery and development collaborations with seven of the world’s...

7Apr2011 | | 0 comments | Continued

(GPRO) Gen-Probe Files Pre-market Approval Application for Prostate Cancer Test

Diagnostic products maker Gen-Probe Inc. (GPRO) has submitted a Pre-market Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its PROGENSA PCA3 assay, a novel molecular test designed to aid the diagnosis...

26Sep2010 | | 0 comments | Continued

(GPRO) Gen-Probe’s Earnings Report Leaps Ahead of Forecast

Diagnostic product maker Gen-Probe Inc. (GPRO) announced second-quarter fiscal 2010 adjusted earnings of 52 cents per share, exceeding the Zacks Consensus Estimate of 49 cents and the year-ago earnings of 45 cents. Net income soared...

31Jul2010 | | 0 comments | Continued

(GPRO) Gen-Probe Invests $50 Million in Pacific Biosciences

Diagnostic product maker Gen-Probe Inc (GPRO) has made a $50 million strategic investment in privately-held DNA sequencing firm Pacific Biosciences (PacBio). The companies will collaborate on developing products based on their...

5Jul2010 | | 0 comments | Continued

(GTF) Cytomedix Analyst Awards Outperform Rating

We are initiating coverage of Cytomedix (GTF) with an ‘Outperform’ rating and near-term price target of $1.50 per share. At this price, we do not believe the market has come to grips with the transformation underway at Cytomedix,...

19Apr2010 | | 0 comments | Continued

(OXBT) Oxygen Biotherapeutics Moves Into New Business

This morning, Oxygen Biotherapeutics (OXBT) announced that the company has begun distribution for its new formulation of Dermacyte (perfluorocarbon oxygen concentrated gel) for the beauty and skin care market. This is essentially...

30Mar2010 | | 0 comments | Continued

(RX) IMS Health Reports Earnings In Line

IMS Health (RX) reported fourth-quarter earnings per share (EPS) of 39 cents, in line with the Zacks Consensus Estimate. However, after adjusting for charges related to restructuring initiatives, asset impairment and others, EPS came...

10Feb2010 | | 0 comments | Continued

(RX) Pharma & Biotech Stock Review – Industry Outlook

The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between...

29Jan2010 | | 0 comments | Continued

(GPRO) Gen-Probe Earns U.S. Food and Drug Administration Approval

Recently, Gen-Probe Inc. (GPRO) announced that it has received the green light from the U.S. Food and Drug Administration (FDA) to market ProParaflu Plus assay. The assay, developed by Prodesse, a wholly-owned subsidiary of Gen-Probe,...

25Nov2009 | | 0 comments | Continued

(RX) IMS Health to be Acquired by Funds Managed by TPG Capital

IMS Health (RX) recently agreed to its acquisition by investment funds managed by TPG Capital (TPG) and the Canada Pension Plan Investment Board (CPPIB) for a total value of $5.2 billion.

The Board of Directors approved the decision...

14Nov2009 | | 0 comments | Continued

(RX) Big Pharma and Biotech – Industry Outlook

The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions...

9Nov2009 | | 0 comments | Continued

(RX) IMS Health Earnings Ahead of Consensus Estimates

This morning, IMS Health (RX) reported third-quarter earnings per share of 40 cents, beating the Zacks Consensus Estimate by 4 cents. However, earnings declined 7% from the year-ago period. Revenues came in at $540.8 million. With clients reining in their spending due to the economic...

22Oct2009 | | 0 comments | Continued

(PRXL) PAREXEL International Corporation – Value – Zacks Rank Buy

PAREXEL International Corporation (PRXL), which provides consulting services to the drug and medical device industries, reported record service revenue that climbed 15.6% in its fiscal second quarter. The company has surprised on estimates 4 consecutive quarters by an average of 9.08%....

2Apr2009 | | 0 comments | Continued

(AMRI) – Albany Molecular Research – earnings of 24 cents per share, far ahead of analyst estimates of 10 cents

Albany Molecular Research, Inc. (AMRI) is weathering the current economic storm in commendable fashion. The company reported strong second-quarter results on Aug 6, forecasted a bullish full-year earnings projection and bears the favor of an accelerating share price.

Company Description

Albany...

9Oct2008 | | 0 comments | Continued

(AMRI) – Albany Molecular Research – earnings of 24 cents per share, far ahead of analyst estimates of 10 cents

Albany Molecular Research, Inc. (AMRI) is weathering the current economic storm in commendable fashion. The company reported strong second-quarter results on Aug 6, forecasted a bullish full-year earnings projection and bears the favor of an accelerating share price.

Company Description

Albany...

7Oct2008 | | 0 comments | Continued

(AMRI) – Albany Molecular Research – earnings of 24 cents per share, far ahead of analyst estimates of 10 cents

Albany Molecular Research, Inc. (AMRI) is weathering the current economic storm in commendable fashion. The company reported strong second-quarter results on Aug 6, forecasted a bullish full-year earnings projection and bears the favor of an accelerating share price.

Company Description

Albany...

2Oct2008 | | 0 comments | Continued

(AMRI) – Albany Molecular Research – earnings of 24 cents per share, far ahead of analyst estimates of 10 cents

Albany Molecular Research, Inc. (AMRI) is weathering the current economic storm in commendable fashion. The company reported strong second-quarter results on Aug 6, forecasted a bullish full-year earnings projection and bears the favor of an accelerating share price.

Company Description

Albany...

1Oct2008 | | 0 comments | Continued

(AMRI) – Albany Molecular Research – A 140% Earnings Surprise

Albany Molecular Research, (AMRI) has set a new 52-high coming off of a spectacular earnings announcement in August. The company has also initiated a Phase I study on a proprietary oncology drug and raised its full-year 2008 outlook.

Company Description

Albany Molecular Research,...

19Sep2008 | | 0 comments | Continued

(AMRI) – Albany Molecular Research – A 140% Earnings Surprise

Albany Molecular Research, (AMRI) has set a new 52-high coming off of a spectacular earnings announcement in August. The company has also initiated a Phase I study on a proprietary oncology drug and raised its full-year 2008 outlook.

Company Description

Albany Molecular Research,...

17Sep2008 | | 0 comments | Continued

(AMRI) – Albany Molecular Research – A 140% Earnings Surprise

Albany Molecular Research, (AMRI) has set a new 52-high coming off of a spectacular earnings announcement in August. The company has also initiated a Phase I study on a proprietary oncology drug and raised its full-year 2008 outlook.

Company Description

Albany Molecular Research,...

10Sep2008 | | 0 comments | Continued

(AMRI) – Albany Molecular Research – A 140% Earnings Surprise

Albany Molecular Research, (AMRI) has set a new 52-high coming off of a spectacular earnings announcement in August. The company has also initiated a Phase I study on a proprietary oncology drug and raised its full-year 2008 outlook.

Company Description

Albany Molecular Research,...

5Sep2008 | | 0 comments | Continued

(ICLR) – ICON Plc – Analysts project an earnings growth rate of 32%

ICON Plc (ICLR) made several key acquisitions and partnerships this year and continues to expand globally. The company also just announced great second-quarter results for its fourth earnings surprise in as many quarters.

Company Description

ICON Plc. provides outsource services...

4Sep2008 | | 0 comments | Continued

(ICLR) – ICON Plc – Analysts project an earnings growth rate of 32%

ICON Plc (ICLR) made several key acquisitions and partnerships this year and continues to expand globally. The company also just announced great second-quarter results for its fourth earnings surprise in as many quarters.

Company Description

ICON Plc. provides outsource services...

23Aug2008 | | 0 comments | Continued

(ICLR) – ICON Plc – an indication that investors are expecting strong earnings from the company

ICON Plc’s (ICLR) share price has been steadily climbing higher for most of 2008, producing excellent returns in a very challenging environment. The company’s second-quarter results were ahead of analyst estimates for the fourth time in the last four quarters, providing additional fundamental...

7Aug2008 | | 0 comments | Continued